Replicor receives IRB approval to conduct a phase I / II trial to test the safety and efficacy of its drug in patients with chronic hepatitis B and hepatitis C.
February 2009 — Replicor announced today that it has received approval to conduct an open label study of the safety and efficacy of its drug in patients with chronic hepatitis B and C in Asia. Patients will receive escalating doses of the drug to determine a safe and effective dose of its drug for treating viral hepatitis in these patients. Primary efficacy endpoints will include reduction in serum viral titers and serum surface antigen levels. Patient enrollment is underway.